Colorectal Cancer
Colorectal Cancer
Advertisement
Benjamin Weinberg, MD, FACPColorectal Cancer | June 30, 2025
Dr. Weinberg recaps key ASCO Annual Meeting research, including MATTERHORN, ATOMIC CHALLENGE, BREAKWATER, and DYNAMIC-III.
Jessica GangaColorectal Cancer | June 27, 2025
Findings from the CheckMate 8HW trial highlight a potential shift in treatment strategy for patients with MSI-H/dMMR mCRC.
Emily MenendezColorectal Cancer | June 24, 2025
A three-year structured exercise program provided significantly longer DFS for patients with colon cancer.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel concludes with an in-depth discussion on the evolving role of ctDNA in colorectal cancer management.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel highlights the BREAKWATER study and explores practical considerations for therapy before biomarker results.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel discusses strategies for IO in CRC, including the ATOMIC trial and adoption of neoadjuvant checkpoint inhibition.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel explores the evolving treatment landscape for patients with MSI-high metastatic colorectal cancer.
Aparna Parikh, MDColorectal Cancer | June 23, 2025
The panel dives into the role of biomarker testing in CRC, noting how next-gen sequencing and MSI testing are essential.
Erica Barnell, MD, PhDColorectal Cancer | June 18, 2025
Dr. Barnell discusses ColoSense's NCCN Guidelines inclusion for CRC and how it impacts the cancer screening landscape.
Benjamin Weinberg, MD, FACPColorectal Cancer | June 10, 2025
Dr. Weinberg explains why combining transcriptomic & genomic features can offer an advantage over prior biomarker ...
Jeanne Tie, MD, MBChBASCO 2025 | June 6, 2025
Professor Tie discusses DYNAMIC-III, a trial using ctDNA to guide chemo escalation in stage III colon cancer.
Christopher Lieu, MDColorectal Cancer | June 5, 2025
Dr. Lieu highlights the randomized trial that looked at atezo with the standard of care for stage III dMMR colon cancer.
Lauren Dembeck, PhDColorectal Cancer | June 5, 2025
The findings are considered practice changing and support EC+mFOLFOX6 as a new SOC for BRAF V600E-mutant mCRC.
Lauren Dembeck, PhDColorectal Cancer | June 5, 2025
The ATOMIC trial showed that adding atezo to mFOLFOX6 significantly improves DFS in stage III colon cancer and dMMR.
Lauren Dembeck, PhDColorectal Cancer | May 29, 2025
Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.
Emily MenendezColorectal Cancer | May 28, 2025
Sotorasib with panitumumab and FOLFIRI has shown promising long-term efficacy results in pretreated KRAS G12C–mutated ...
Christopher Lieu, MDLiver Cancer | May 16, 2025
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Christopher Lieu, MDColorectal Cancer | May 16, 2025
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
Emily MenendezColorectal Cancer | May 9, 2025
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Alan P. Venook, MDColorectal Cancer | May 8, 2025
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Advertisement